



July 17, 2018

The Honorable Susan Brooks  
1505 Longworth House Office Building  
United States House of Representatives  
Washington, DC 20515

The Honorable Anna Eshoo  
241 Cannon House Office Building  
United States House of Representatives  
Washington, DC 20515

Dear Representatives Brooks and Eshoo,

On behalf of the Biotechnology Innovation Organization (BIO), I am writing express our strong support for H.R. 6378, the "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018". I wish to commend you for introducing this legislation and look forward to continuing to work with you on this important measure.


BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO's members are committed to investing in, developing, and delivering innovative vaccines, therapeutics, and diagnostic tools that are transforming how we protect, treat, and cure people from devastating infectious diseases. Many of BIO's members are active partners with the U.S. government to strengthen our national health security through the development and stockpile of medical countermeasures (MCM) against the myriad threats facing our nation. The value that these MCMs offer to first responders, patients and their caregivers, and the global community is phenomenal.

BIO was pleased to see the Act continue to provide support for critical preparedness programs such as the Bioshield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and Strategic National Stockpile (SNS) – all of which are necessary to ensure that we can maintain a robust medical countermeasures enterprise that can address known and unknown threats. We are also pleased to see that significant threats such pandemic influenza, emerging infectious diseases, and antimicrobial resistance (AMR) are specifically recognized in the Act and that BARDA has been granted the authority to implement research, development, and procurement activities to address these dangerous threats.

We believe that pull incentives are needed to stimulate investment for innovative medicines that address the growing threat of AMR and urge Congress to address this issue through this Act or another legislative vehicle soon.

BIO thanks you for your commitment to our national health security and your important work to ensure that our nation is adequately prepared to respond to the myriad threats we face domestic and abroad.

With Sincerest Regards,

  
James C. Greenwood  
President and CEO